Literature DB >> 12529928

Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier.

Michel Demeule1, Anthony Régina, Julie Jodoin, Alain Laplante, Claude Dagenais, France Berthelet, Albert Moghrabi, Richard Béliveau.   

Abstract

1. The blood-brain barrier (BBB) contributes to brain homeostastis and fulfills a protective function by controlling the access of solutes and toxic substances to the central nervous system (CNS). The efflux transporter P-glycoprotein (P-gp) is a key element of the molecular machinery that confers special permeability properties to the BBB. 2. P-gp, which was initially recognized for its ability to expel anticancer drugs from multidrug-resistant cancer cells, is strongly expressed in brain capillaries. Its expression in the BBB limits the accumulation of many hydrophobic molecules and potentially toxic substances in the brain. 3. The purpose of this review is to summarize the current state of knowledge about the expression of P-gp, its cellular localization as well as its possible functions in the BBB.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12529928     DOI: 10.1016/s1537-1891(02)00201-x

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  52 in total

Review 1.  Blood-Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies.

Authors:  Loqman A Mohamed; Shashirekha Markandaiah; Silvia Bonanno; Piera Pasinelli; Davide Trotti
Journal:  AAPS J       Date:  2017-08-04       Impact factor: 4.009

Review 2.  Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders.

Authors:  Gloria Lee; Reina Bendayan
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

Review 3.  Strategies to target drugs to gliomas and CNS metastases of solid tumors.

Authors:  B Milojkovic Kerklaan; O van Tellingen; A D R Huitema; J H Beijnen; W Boogerd; J H M Schellens; D Brandsma
Journal:  J Neurol       Date:  2015-10-17       Impact factor: 4.849

Review 4.  Dynamics of CNS barriers: evolution, differentiation, and modulation.

Authors:  N Joan Abbott
Journal:  Cell Mol Neurobiol       Date:  2005-02       Impact factor: 5.046

Review 5.  State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer.

Authors:  Alessandro Inno; Vincenzo Di Noia; Ettore D'Argento; Alessandra Modena; Stefania Gori
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 6.  Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's disease.

Authors:  Jens Pahnke; Olaf Wolkenhauer; Markus Krohn; Lary C Walker
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

Review 7.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 8.  Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.

Authors:  Wolfgang Löscher; Heidrun Potschka
Journal:  NeuroRx       Date:  2005-01

Review 9.  Magnetic resonance-guided focused ultrasound: a new technology for clinical neurosciences.

Authors:  Ferenc A Jolesz; Nathan J McDannold
Journal:  Neurol Clin       Date:  2013-11-08       Impact factor: 3.806

10.  Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.

Authors:  Mohamed Ismail Nounou; Chris E Adkins; Evelina Rubinchik; Tori B Terrell-Hall; Mohamed Afroz; Tim Vitalis; Reinhard Gabathuler; Mei Mei Tian; Paul R Lockman
Journal:  Pharm Res       Date:  2016-08-15       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.